Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + bevacizumab versus sunitinib in untreated advanced renal cell carcinoma
2014-004684-20Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Atezolizumab + bevacizumab with Sunitinib (2 arms). Primary endpoint: Progression-free survival. Started Mar 2015; status: active.
02
Drugs
atezolizumabbevacizumabsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2014-004684-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004684-20.